XERS News and Press, Xeris Pharmaceuticals Inc. From 08/10/22

Achieved record net product revenue of $25.3M – a 15% increase from Q1 ’22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short-term investments Reaffirms full-year total net produc...

Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q2 earnings results on Wednesday, August 10th, before market open. The consensus EPS Estimate is -$0.22 (-4.8% Y/Y) and the consensus Revenue Estimate is $25.53M (+155.3% Y/Y). Over the last 2 years, XERS ...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing differentiated and innovative products across a range of therapies, toda...

Xeris Biopharma ( NASDAQ: XERS ) announced on Monday that the terms of its commercialization agreement for hypoglycemia therapy Ogluo would change as the UK-based biopharmaceutical company has agreed to acquire its partner Tetris Pharma. In July 2021, Xeris ( XERS ) jo...

Tetris will be acquired by Arecor and continue to commercialize Ogluo in the UK and EEA Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology and neurology, toda...

At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...

Xeris recently reported encouraging Q1 earnings. The company's commercial products are off to a strong start, including their recently launched product, Recorlev. Xeris reaffirmed its full-year net product revenue guidance to be in the range of $105M to $120M. Strongbridge synergies a...

Micro-cap pharma stock Xeris Biopharma (NASDAQ:XERS) has added more than a quarter of value to record its biggest ever intraday gain on Monday after the Chief Executive Paul R. Edick disclosed the purchase of 100,000 of company shares. Mr. Edick who is also the chairman of the Xeris...

Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced it is presenting new data on the burden of illness in Cushing’s sy...